Crestline Management LP bought a new position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 24,960 shares of the company's stock, valued at approximately $736,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Groupama Asset Managment acquired a new position in shares of Immunocore during the 4th quarter valued at $17,700,000. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after acquiring an additional 200,373 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after acquiring an additional 196,530 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Immunocore during the 4th quarter valued at $5,697,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after acquiring an additional 109,206 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have commented on IMCR shares. Oppenheimer boosted their price objective on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley restated an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th. JPMorgan Chase & Co. cut their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $58.13.
View Our Latest Analysis on IMCR
Immunocore Price Performance
Shares of IMCR stock traded up $0.87 during trading hours on Thursday, hitting $28.56. The company had a trading volume of 299,144 shares, compared to its average volume of 429,168. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -30.06 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a 12 month low of $23.15 and a 12 month high of $58.36. The firm's fifty day moving average is $28.71 and its 200 day moving average is $30.09.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business's revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.49) EPS. On average, sell-side analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the business's stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.40% of the company's stock.
Immunocore Company Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Articles
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
